Products for Research Use Only

Vemircopan

CAT: 0804-HY-139588-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-139588-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria[1][2][3].
CAS Number
2086178-00-7
Product Name Alternative
ALXN2050; ACH 0145228; ACH-5228
UNSPSC
12352005
Target
Complement System; Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vemircopan.html
Purity
98.61
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
C[C@]12[C@](C2)([H])N([C@@H](C1)C(NC3=C(C=CC(Br)=N3)C)=O)C(CN4C5=CC=C(C6=CN=C(C)N=C6)C=C5C(C(C)=O)=N4)=O
Molecular Formula
C29H28BrN7O3
Molecular Weight
602.48
References & Citations
[1]Browett P J, et al. Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: interim data from a phase 2 open-label proof-of-concept study[J]. Blood, 2022, 140 (Supplement 1) : 717-719.|[2]Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. 2024 May 16:1-11. |[3]Versino F, et al. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. Int J Lab Hematol. 2024 May;46 Suppl 1:43-54.|[4]Prasad RR, et al. An intracellular complement system drives metabolic and proinflammatory reprogramming of vascular fibroblasts in pulmonary hypertension. JCI Insight. 2025 Feb 13;10 (6) :e184141.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
IL-6